Results
1 -
8 of
8Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers, Cancer Chemotherapy and Pharmacology Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors, Cancer Chemotherapy and Pharmacology A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates, Cancer Chemotherapy and Pharmacology Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines, Journal of Hematology & Oncology Erratum to: Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines, Journal of Hematology & Oncology DNA damage control, Science-Business eXchange A niche play for stem cells, Science-Business eXchange